Pharmacovigilance Summary Report: Apr 1st to June 30th 2026 (Q4)
- Version
- Download 5
- File Size 2.81 MB
- File Count 1
- Create Date July 27, 2026
- Last Updated August 26, 2026
Pharmacovigilance Summary Report: Apr 1st to June 30th 2026 (Q4)
The Pharmacy and Poisons Board is the National Regulatory Authority established under the Pharmacy and Poisons Act, Chapter 244 of the Laws of Kenya. The Board is mandated to protect and promote public health by regulating the pharmacy profession and ensuring access to quality, safe, and effective health products and technologies (HPTs).
Further, Rule 5 of the Pharmacy and Poisons (Pharmacovigilance and Post-Market Surveillance) Rules, 2022 mandates the Board to establish and maintain a National Pharmacovigilance Centre responsible for coordinating the national pharmacovigilance and post-market surveillance system, including receiving, collating, assessing, and maintaining information on adverse events associated with authorized HPTs.
As part of this mandate, the Board provides quarterly pharmacovigilance reports to stakeholders as a feedback mechanism, aiming to enhance collaboration and encourage the timely reporting of adverse events. In this quarter, the National Pharmacovigilance Centre engaged in several pharmacovigilance activities in an effort to ensure the quality, safety and efficacy of Health products and Technologies.
Below is a summary of Pharmacovigilance activities conducted between April 1st to June 30th 2026.
Attached Files
